WEST Search History

DATE: Wednesday, February 12, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L8	mcm-2.ab.	1	L8
L7	(MCM2 or anti-MCM2).clm.	0	L7
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L6	(MCM2 or anti-MCM2).ab.	8	L6
DB=USPT; PLUR=YES; OP=OR			
L5	(bcl-2 or bcl2) same (cervical or cervix)	8	L5
L4	(bcl-2 or bcl2).ab. and (cervical or cervix).ab.	0	L4
DB=JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L3	(bcl-2 or bcl2) and (cervical or cervix)	4	L3
DB=USPT; PLUR=YES; OP=OR			
L2	(bcl-2 or bcl2).clm. and (cervix or cervical).clm.	1	L2
DB=EPAB,DWPI; PLUR=YES; OP=OR			
L1	(Ramaekers-F$).in.	6	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 14:23:40 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 14:27:37 ON 12 FEB 2003

L1 591 S (MCM2 OR "MINICHROMOSOME MAINTENANCE PROTEIN 2")
L2 89 S L1 AND (CANCER? OR TUMOR? OR NEOPLAS? OR METAST?)
L3 5 S L2 AND PY<=1998
L4 2 DUP REM L3 (3 DUPLICATES REMOVED)
L5 1313 S (LASKEY-R? OR WILLIMAS-G? OR COLEMAN-N?)/AU
L6 114 S L5 AND MCM?
L7 48 S L6 AND PY<=1998
L8 11 DUP REM L7 (37 DUPLICATES REMOVED)

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for #17 AND (carcinoma OR cancer* OR tumor* OR ne Preview Go

Clear

Limits Preview/Index **History** Clipboard Details

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez PubMed

PubMed Services

Related Resources

Search	Most Recent Queries	Time	Result
#19	Search **#17 AND (carcinoma OR cancer* OR tumor* OR neopla* OR metast*)**	14:46:59	39
#18	**Related Articles** for **PubMed** (Select **12565771**)	14:44:57	102
#17	Search **(anti-MCM2 OR mcm2)**	14:44:46	157
#16	Search **MCM2** Field: **All Fields,** Limits: **Publication Date to 1998**	14:43:35	57
#15	Search **MCM2** Field: **All Fields,** Limits: **Publication Date to 1999**	14:43:19	75
#14	Search **MCM2**	14:43:03	157
#13	Search **#12 AND MCM***	14:42:51	1
#12	**Related Articles** for **PubMed** (Select **9843993**)	14:39:58	150
#10	Search **laskey r AND williams G** Field: **Author,** Limits: **Publication Date from 1998 to 1998**	14:38:47	2
#5	Search **#3 AND (BCL2 OR BCL-2)**	13:22:50	15
#3	Search **#2** Field: **All Fields,** Limits: **Publication Date to 1996**	13:21:36	263
#2	**Related Articles** for **PubMed** (Select **8691340**)	13:20:48	363
#1	Search **harmsel B** Field: **All Fields,** Limits: **Publication Date from 1996 to 1996**	13:20:45	1

Clear History

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642GXN

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:53:26 ON 12 FEB 2003

=> file pctfull uspatfull europatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'PCTFULL' ENTERED AT 14:53:40 ON 12 FEB 2003
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 14:53:40 ON 12 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 14:53:40 ON 12 FEB 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s mcm2 (s) (carcinoma or cancer? or tumor? or neoplas? or metast?)
L1 9 MCM2 (S) (CARCINOMA OR CANCER? OR TUMOR? OR NEOPLAS? OR METAST?)

=> d ibib kwic 1-9

L1 ANSWER 1 OF 9 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002079489 PCTFULL ED 20021022 EW 200241
TITLE (ENGLISH): METHOD OF IDENTIFYING RENALGENERATIVE AGENTS USING DIFFERENTIAL GENE EXPRESSION
TITLE (FRENCH): PROCEDE PERMETTANT D'IDENTIFIER LES AGENTS PARTICIPANT A LA FORMATION DES REINS AU MOYEN D'UNE EXPRESSION GENIQUE DIFFERENTIELLE
INVENTOR(S): PEYMAN, John, A.; LEHTONEN, Eero; CRASTA, Oswald, R.; CATES, Richard, L.
PATENT ASSIGNEE(S): CURAGEN CORPORATION, for all designates States except US; BIOGEN, INC., for all designates States except US; PEYMAN, John, A., for US only; LEHTONEN, Eero, for US only; CRASTA, Oswald, R., for US only; CATES, Richard, L., for US only
AGENT: ELRIFI, Ivor, R.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

	WO 2002079489	A2 20021010
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG	
APPLICATION INFO.:	WO 2002-US10017	A 20020401
PRIORITY INFO.:	US 2001-60/280,258	20010330

DETD m90365 Catenin ganima, plakoglobin 87 2.09
af144095 Myosin 15, unconventional myosin 88 1.94
s76831 Tropomodulin 89 1.72
afI04414 Large **tumor** suppressor 1 (Latsl) 90 1.70
akO14169 Ch-tog, colon/hepatic **tumor** over-expressed gene 91 1.64
aa218430 Dynein 92 1.63
aa870409 Homolog of human endothelial actin-binding protein 93 1.56
Transcription Factors and Nuclear Proteins
x55781 Pax2,. . . Zinc finger protein 131 homolog 113 1.62
af 182040 Cbf 1, Suppressor of Hairless [Su(H)I/Lag- I/RBP-Jkappa 114 1.54
m55512 WT- 1, Willms' **tumor** gene- 1, 4 cDNA fragments 115 1.21
Nuclear receptors
Arp-1, apolipoprotein regulatory protein-1, orphan nuclear receptor in the
uO7635 COUP family 116 1.55
Endoplasmic. . . light chain 3, non-muscle myosin 199 51
af'.)33340 Synbindin 200 59
akOO8947 Coronin 201 67
x72711 Replication factor C, large subunit 202 51
d86725 **MCM2**/BM28, minichromosome maintenance 2 203 -i.56
ai528428 Variant historic H3.3 204 61
af294327 Ran binding protein 5 205 67
116846 Btgl, B-cell translocation gene-I. . .

L1 ANSWER 2 OF 9 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER:	2002022777 PCTFULL ED 20020705 EW 200212
TITLE (ENGLISH):	CELLULAR GENES INVOLVED IN ONCOGENESIS, PRODUCTS OF SAID GENES AND THEIR DIAGNOSTIC AND THERAPEUTIC USES
TITLE (FRENCH):	GENES CELLULAIRES IMPLIQUES DANS L'ONCOGENESE, LES PRODUITS DE CES GENES ET LEURS APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
INVENTOR(S):	PATERLINI-BRECHOT, Patrizia; BRECHOT, Christian
PATENT ASSIGNEE(S):	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), for all designates States except US; PATERLINI-BRECHOT, Patrizia, for US only; BRECHOT, Christian, for US only
AGENT:	BLOT, Philippe
LANGUAGE OF FILING:	French
LANGUAGE OF PUBL.:	French
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

	NUMBER	KIND	DATE
	WO 2002022777	A2	20020321
DESIGNATED STATES	CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
APPLICATION INFO.:	WO 2001-FR2509	A	20010731
PRIORITY INFO.:	FR 2000-00/11826		20000915
	US 2001-60/292,920		20010523

DETD Les proteines MCM sont une famille de proteines incluant six membres (**MCM2** a 7) hautement conserves de la levure a l'homme. Les six proteines MCM forment un complexe qui a une activite ADN helicase. . . l'ADN une seule fois par cycle (Kearsey et ai., 1998). Les proteines MCM sont hautement exprimees dans les cellules io proliferatives et **neoplasiques**. L'ADNc de ce nouveau gene humain MCM8 a ete clone par les inventeurs a partir de foie normal (SEQ ID n012).. . . a ete produit. Une analyse par Western Blot a montre qu'une forme tronquee de MCM8 (33kD) est specifiquement exprimee dans le tissu **tumoral** (77T) par comparaison au tissu sain. La taille de cette proteine est compatible avec une forme de la proteine MCM8 tronquee. .

L1 ANSWER 3 OF 9 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER:	2002008764 PCTFULL ED 20020814
TITLE (ENGLISH):	DETECTION OF ABNORMALITIES LEADING TO CERVICAL MALIGNANCY
TITLE (FRENCH):	DETECTION D'ANOMALIES ENTRAINANT UNE TUMEUR MALIGNE CERVICALE
INVENTOR(S):	DOORBAR, John
PATENT ASSIGNEE(S):	MEDICAL RESEARCH COUNCIL; DOORBAR, John
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 2002008764	A1	20020131

DESIGNATED STATES	US GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2001-GB1176 A 20010316
PRIORITY INFO.:	GB 2000-0018140.4 20000724

DETD Binding molecules directed against Cdc6, and also those against **MCM2**, MCM3, MCM4, MCM5, MCM 6 or MCM7 are effective in marking cellular growth abnormality, as are antibodies against PCNA and Ki67 or Ki5134 (for example see Southern, S. A. & Herrington, C. S. (1998) **Cancer** Research 58, 2941-2945 or Follen Mitchell, M. et al., (1996) Journal of the National **Cancer** Institute Mono&aphs 21, 17-25). All these proteins can be considered proliferation markers. Of particular interest in the context of screening is the. . .

These include Cdc6 and proteins of the **MCM2**-7 family (**MCM2**, MCM3, MCM4, MCM5, MCM6 and MCM7). Williams et al. (1997) (Proc. Natl. Acad. Sci. USA, 1997, 94: 142-147) reported that human HeLa. . . that specific binding molecules directed to proteins of the preinitiation complex of DNA replication, particularly Cdc6 or MCM proteins (such as MCM5, **MCM2**. MCM3, MCM4. MCM6 and MCM7) are useful for detection of atypical or **neoplastic** cells.

L1 ANSWER 4 OF 9 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2001066753 PCTFULL ED 20020822
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS
TITLE (FRENCH): NOUVEAUX GENES HUMAINS ET LEURS PRODUITS D'EXPRESSION
INVENTOR(S): WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, William, Lee; STACHE-CRAIN, Birgit
PATENT ASSIGNEE(S): CHIRON CORPORATION; HYSEQ INC.; WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, William, Lee; STACHE-CRAIN, Birgit
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001066753	A2	20010913

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US7787 A 20010309
PRIORITY INFO.: US 2000-60/188,609 20000309

L1 ANSWER 5 OF 9 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001064835 PCTFULL ED 20020822
TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
TITLE (FRENCH): NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES
INVENTOR(S): TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.
PATENT ASSIGNEE(S): HYSEQ, INC.; TANG, Y., Tom; LIU, Chenghua; DRMANAC, Radoje, T.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001064835	A2	20010907

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US4927 A 20010226
PRIORITY INFO.: US 2000-09/515,126 20000228
US 2000-09/577,409 20000518
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L1 ANSWER 6 OF 9 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2000060066 PCTFULL ED 20020515
TITLE (ENGLISH): PROTEIN-PROTEIN FROM S. CEREVISIAE AND METHODS OF USING SAME

TITLE (FRENCH): COMPLEXES PROTEINE-PROTEINE DE S. CEREVISIAE ET LEURS METHODES D'UTILISATION

INVENTOR(S): GIOT, Loic; MANSFIELD, Traci, A.

PATENT ASSIGNEE(S): CURAGEN CORPORATION; GIOT, Loic; MANSFIELD, Traci, A.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000060066	A1	20001012
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US8399	A	20000330
PRIORITY INFO.:	US 1999-60/127,352		19990401
	US 2000-60/127,352		20000201
	US 2000-60/127,352		20000329

DETD . . . B kinase gamma catalytic chain, ykrO48c p21817 RYR1 Ryanodine re(
skeletal muscle isoform
ycIO59c p46821 MAP1B Microtubule-associated protein 1B ygI2011 c p49736 **MCM2** DNA replicatic
ycIO63w qO5682 CALD1 Caldesmon/CDM ylr423c qO2224 CENPE Centromeric p
ycrO09c p15924 DSP Desmoplakin I and 11 ybr1O8w pO4280 PRB1 Salivary. . . ZNF183 zinc finger pro
TFIID
ydIO12c p51531 SMARCA2 Possible global transcription activator SNF2L2/BRM ydrl 51 c p26651 ZFP36 Tristetraprolinf
ydIO12c q1105711 MN1 Probable **tumor** suppressor protein MNI
ydrl 51 c p47974 BRF2 TIS 1 1 D proteii
response fact(
ydIO12c q93074 KIAA0192 Hypothetical protein KIAAO 1. . .

L1 ANSWER 7 OF 9 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1999021014 PCTFULL ED 20020515

TITLE (ENGLISH): DETERMINATION OF CELLULAR GROWTH ABNORMALITY

TITLE (FRENCH): DETERMINATION D'ANOMALIES DE LA CROISSANCE CELLULAIRE

INVENTOR(S): LASKEY, Ronald, Alfred; WILLIAMS, Gareth, Haydn; COLEMAN, Nicholas

PATENT ASSIGNEE(S): CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED; LASKEY, Ronald, Alfred; WILLIAMS, Gareth, Haydn; COLEMAN, Nicholas

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9921014	A1	19990429
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB3153	A	19981021
PRIORITY INFO.:	GB 1997-9722217.8		19971021
	GB 1997-9724134.3		19971114

GB 1998-9804156.9 19980226
GB 1998-9810560.4 19980515
GB 1998-9817075.6 19980805

ABEN Determination of cellular growth abnormality, particularly **cancerous** abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, **MCM2**, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon,. . . lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of **cancerous** and pre-**cancerous** cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of **metastatic** sarcoma and **carcinoma**.

ABFR Determination d'anomalies de la croissance cellulaire, en particulier de l'anomalie **cancereuse**, par detection de polypeptides cibles ou d'ARNm codant lesdits polypeptides, ces polypeptides cibles etant des membres du complexe de preinitiation de la replication d'ADN dans des tissus, cellules ou fluides. Lesdits polypeptides cibles sont CDC6, **MCM2**, MCM3, MCM4, MCM5, MCM6 et MCM7. Les prelevements a analyser comportent des tissus du col de l'uterus (a la fois. . . et des voies urinaires (a la fois prelevements par biopsie et par frottis), pour determiner l'anomalie de la croissance cellulaire **cancereuse** et precancereuse, ainsi que des cellules prelevees dans l'urine, le sang et le serum, pour determiner les malignites hematologiques et mettre en evidence la presence d'un sarcome et d'un carcinome **metastasique**.

DETD . . . directed to proteins of the preinitiation complex of DNA replication, particularly Cdc6 or MCM proteins (such as MCM5 but also exemplified herein for **MCM2**. MCM3r MCM4. MCM6 and MCM7) have exceptional diagnostic value for early detection of atypical or **neoplastic** cells. On cervical samples subject to antigen retrieval (pressure cooking or autoclaving), which samples are formalin fixed and paraffin embedded, anti-Cdc6 and anti-MCM. . .

The high degree of specificity observed in the experiments described below with anti-Cdc6 antibodies and anti-MCM antibodies, including various anti-**MCM2**, anti-MCM3. anti-MCM4, 15 anti-MCM5, anti-MCM6 and anti-MCM7 antibodies, tested on a range of breast **cancers** provides for immunocytological and biochemical approaches for diagnosis of breast **cancer**. Such may be applied to breast biopsies or fine needle aspiration (FNA) specimens or samplings of fluid from breast ducts, 20 allowing for. . .

EXAMPLE 19 - Staining of normal breast and breast **carcinoma** tissues with anti-CDC6, anti-**MCM2**, anti-MCM5, anti-MCM7 and pan-MCM antibodies.

5 Histological specimens of normal breast (recipients of breast reduction operations) and biopsy-proven ductal and lobular **carcinomas** were stained with antibodies against CDC6, **MCM2**,

MCM5 and MCM7 and a pan-MCM antibody. The anti-**MCM2** antibody was the BM28 mouse monoclonal antibody available commercially 10 from Transduction Laboratories (see their 1998 Antibody Catalog). Staining was performed individually for. . .

EXAMPLE 21 - Staining of normal colon and **carcinoma** of the colon using antibodies against **MCM2**, MCM5, MCM7, pan-MCM and 25 CDC6.

20 EXAMPLE 22 - Staining of normal tissue and **carcinoma** of the lung, with antibodies against **MCM2**, MCM5, MCM7 and pan-MCM.

Paraffin embedded histology specimens of biopsies or resections from patients with squamous cell **carcinoma** or adenocarcinoma of
the lung were stained separately with anti-**MCM2**, anti-MCM5.

EXAMPLE 23 - Staining of bladder, both normal and **carcinoma**, with anti-**MCM2**, anti-MCM5, anti-MCM7, pan-MCM and anti-CDC6 antibodies.

Histological specimens from biopsies of transitional cell **carcinomas** taken at cystoscopy were stained with anti-**MCM2**,
anti-MCM5, anti-MCM7, pan-MCM and anti-CDC6 antibodies.

L1 ANSWER 8 OF 9 USPATFULL

ACCESSION NUMBER:	2003:30382 USPATFULL
TITLE:	Novel nucleic acids and polypeptides
INVENTOR(S):	Tang, Y. Tom, San Jose, CA, UNITED STATES Liu, Chenghua, San Jose, CA, UNITED STATES Zhou, Ping, San Jose, CA, UNITED STATES Asundi, Vinod, Foster City, CA, UNITED STATES Ren, Feiyan, Cupertino, CA, UNITED STATES Zhao, Qing A., San Jose, CA, UNITED STATES Xue, Aidong J., Sunnyvale, CA, UNITED STATES Zhang, Jie, Campbell, CA, UNITED STATES Wehrman, Tom, Stanford, CA, UNITED STATES Wang, Jian-Rui, Cupertino, CA, UNITED STATES Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022329	A1	20030130
APPLICATION INFO.:	US 2002-125237	A1	20020417 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 2000-668317, filed on 22 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-552929, filed on 18 Apr 2000, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
LINE COUNT:	11768

DETD . . . 568 99

	2034			
48	2063	U47924	Homo sapiens C8	1400
	100			
	2064			
49	2119	AF243495	Homo sapiens	2530
	99			
	2120		hepatocellular	
	2121		**carcinoma**-	

	2122		associated antigen 67	
50	2138	U37429	Caenorhabditis	314
40	2139		elegans similar to	
	2140		C18F10.5	
51	2141	X12791	Homo sapiens 19kD. . .	
BcDNA.HL05936				
81	3138	AF084256	Homo sapiens beta	129
62			glucuronidase isoform d	
82	3160	AL035461	Homo sapiens	3096
100	3161		dJ967N21.5 (novel **MCM2**/3/5 family member)	
83	3382	AF006129	Acipenser	66
26			schrenckii cytochrome b	
84	3503	AF074016	Homo sapiens	334
37			nonsense-mediated mRNA decay trans-	

. . .

L1 ANSWER 9 OF 9 USPATFULL

ACCESSION NUMBER: 2001:178827 USPATFULL

TITLE: Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies

INVENTOR(S): Laskey, Ronald A., Cambridge, United Kingdom
Williams, Gareth H., Cambridge, United Kingdom
Coleman, Nicholas, Cambridge, United Kingdom

PATENT ASSIGNEE(S): Cancer Research Campaign Technology Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6303323	B1	20011016	
APPLICATION INFO.:	US 1998-175947		19981021	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 1997-22217	19971021	
	GB 1997-24134	19971114	
	GB 1998-4156	19980226	
	GB 1998-10560	19980515	
	GB 1998-17075	19980805	
	US 1997-71245P	19971222	(60)
	US 1998-86885P	19980527	(60)
	US 1998-95966P	19980810	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Nickol, Gary B
LEGAL REPRESENTATIVE: Nixon & Vanderhye P.C.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Determination of cellular growth abnormality, particularly **cancerous** abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the

preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, **MCM2**, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon,. . . lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of **cancerous** and pre-**cancerous** cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of **metastatic** sarcoma and **carcinoma**.

SUMM . . . of the preinitiation complex of DNA replication, particularly Cdc6 or MCM proteins (such as MCM5 but also exemplified herein for **MCM2**, MCM3, MCM4, MCM6 and MCM7) have exceptional diagnostic value for early detection of atypical or **neoplastic** cells. On cervical samples subject to antigen retrieval (pressure cooking or autoclaving), which samples are formalin fixed and paraffin embedded,. . .

SUMM The high degree of specificity observed in the experiments described below with anti-Cdc6 antibodies and anti-MCM antibodies, including various anti-**MCM2**, anti-MCM3, anti-MCM4, anti-MCM5, anti-MCM6 and anti-MCM7 antibodies, tested on a range of breast **cancers** provides for immunocytological and biochemical approaches for diagnosis of breast **cancer**. Such may be applied to breast biopsies or fine needle aspiration (FNA) specimens or samplings of fluid from breast ducts,. . .

DETD Staining of Normal Breast and Breast **Carcinoma** Tissues with Anti-CDC6, Anti-**MCM2**, Anti-MCM5, Anti-MCM7 and Pan-MCM Antibodies

DETD Histological specimens of normal breast (recipients of breast reduction operations) and biopsy-proven ductal and lobular **carcinomas** were stained with antibodies against CDC6, **MCM2**, MCM5 and MCM7 and a pan-MCM antibody. The anti-**MCM2** antibody was the BM28 mouse monoclonal antibody available commercially from Transduction Laboratories (see their 1998 Antibody Catalog). Staining was performed. . .

DETD Staining of Normal Colon and **Carcinoma** of the Colon Using Antibodies Against **MCM2**, MCM5, MCM7, Pan-MCM and CDC6

DETD Staining of Normal Tissue and **Carcinoma** of the Lung, with Antibodies Against **MCM2**, MCM5, MCM7 and Pan-MCM

DETD Paraffin embedded histology specimens of biopsies or resections from patients with squamous cell **carcinoma** or adenocarcinoma of the lung were stained separately with anti-**MCM2**, anti-MCM5, anti-MCM7 and pan-MCM antibodies. The specimens were prepared as described for breast tissue in Example 19. Staining was compared. . .

DETD Staining of Bladder, Both Normal and **Carcinoma**, with Anti-**MCM2**, Anti-MCM5, Anti-MCM7, Pan-MCM and Anti-CDC6 Antibodies

DETD Histological specimens from biopsies of transitional cell **carcinomas** taken at cystoscopy were stained with anti-**MCM2**, anti-MCM5, anti-MCM7, pan-MCM and anti-CDC6 antibodies.

=> file .gary

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.30	16.51

FILE 'MEDLINE' ENTERED AT 14:54:56 ON 12 FEB 2003

FILE 'CANCERLIT' ENTERED AT 14:54:56 ON 12 FEB 2003

FILE 'BIOSIS' ENTERED AT 14:54:56 ON 12 FEB 2003

FILE 'EMBASE' ENTERED AT 14:54:56 ON 12 FEB 2003

FILE 'SCISEARCH' ENTERED AT 14:54:56 ON 12 FEB 2003

=> s mcm2 and (carcinoma or cancer? or tumor? or neoplas? or metast?)
   2 FILES SEARCHED...
L2   86 MCM2 AND (CARCINOMA OR CANCER? OR TUMOR? OR NEOPLAS? OR METAST?)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3   35 DUP REM L2 (51 DUPLICATES REMOVED)

=> s l3 and py<=1998
   2 FILES SEARCHED...
   4 FILES SEARCHED...
L4   2 L3 AND PY<=1998

=> d ibib abs 1-2

L4   ANSWER 1 OF 2   MEDLINE
ACCESSION NUMBER: 1998087156   MEDLINE
DOCUMENT NUMBER: 98087156   PubMed ID: 9427284
TITLE: Nuclear accumulation of Saccharomyces cerevisiae Mcm3 is
                    dependent on its nuclear localization sequence.
AUTHOR: Young M R; Suzuki K; Yan H; Gibson S; Tye B K
CORPORATE SOURCE: Department of Biological Science, Faculty of Science,
                    Hiroshima University, Kagamiyama, Japan.
CONTRACT NUMBER: GM17151 (NIGMS)
     GM34190 (NIGMS)
SOURCE: GENES TO CELLS, **(1997 Oct)** 2 (10) 631-43.
                    Journal code: 9607379. ISSN: 1356-9597.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199802
ENTRY DATE: Entered STN: 19980217
                    Last Updated on STN: 19980217
                    Entered Medline: 19980205
AB   BACKGROUND: The proteins of the **Mcm2**-7 family are required for
     the initiation of DNA replication. In Saccharomyces cerevisiae the nuclear
     envelope does not break down during the mitotic phase of the cell cycle.
     Large nuclear proteins, such as the Mcm proteins, which accumulate in the
     nucleus during specific portions of the cell cycle, must have regulated
     mechanisms to direct their entry into the nucleus. RESULTS: We have
     identified a nuclear localization sequence (NLS) in Mcm3, and demonstrated
     that it is necessary for the translocation of Mcm3 into the nucleus and
     sufficient for directing Escherichia coli beta-galactosidase to the
     nucleus. Immediately adjacent to the nuclear localization sequence are
     four potential sites for phosphorylation by Cdc28. Mutagenesis of all four
     sites has no immediate phenotypic effect on cell growth or viability, nor
     does it affect nuclear accumulation of Mcm3, although two-dimensional
     protein gel analysis has shown that at least some of these sites are
     normally phosphorylated in vivo. Substitution of the Mcm3 NLS by the SV40
     large T-antigen NLS also directs the nuclear accumulation of the
     Mcm3-T-antigen protein, although cell growth is compromised. Replication
     activity in cells bearing either the Mcm3-Cdc28 phosphorylation site
     mutations or the Mcm3 T-antigen NLS substitution, as measured by plasmid
     stability assays, is comparable to activity in wild-type cells.
     CONCLUSIONS: The Mcm3 protein is imported into the nucleus by a specific
     NLS. The cell cycle specific nuclear accumulation of Mcm3 appears to be a
     result of nuclear retention or nuclear targeting, rather than nuclear
     import regulated through the NLS.

L4 ANSWER 2 OF 2 MEDLINE

ACCESSION NUMBER: 86124104 MEDLINE

DOCUMENT NUMBER: 86124104 PubMed ID: 3937306

TITLE: [Detection of cells resistant to the cytotoxic action of CCl4 in the hepatocyte populations of rats following a single exposure to 4-dimethylaminoazobenzene combined with subsequent injections of the **tumor** promoter phenobarbital].
Vyiavlenie rezistentnykh k tsitotoksicheskomu deistviiu CCl4 kletok v populiatsiiakh gepatotsitov krys posle odnokratnogo vozdeistviia 4-dimetilaminoazobenzolom v sochetanii s posleduiushchimi in''ektsiiami opukholevogo promotora fenobarbitala.

AUTHOR: Zakharova N V; Khodosova I A; Kudriatsev B N; Fel' V Ia

SOURCE: TSITOLOGIIA, **(1985 Nov)** 27 (11) 1280-4.
Journal code: 0417363. ISSN: 0041-3771.

PUB. COUNTRY: USSR

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Russian

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198603

ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19860312

AB It is found that hepatic cells of intact rats measuring 129-192 **mcm2** are resistant to cytotoxical action of carbon tetrachloride (CCl4). After a single interperitoneal injection of the carcinogen 4-dimethylaminoazobenzene, small hepatocytes (64-128 **mcm2**) appear to be maintained for one month following five injections of phenobarbital. These small hepatocytes are resistant to cytotoxical action of CCl4. The resistance was studied using a cytochemical test on succinate dehydrogenase. A direct dependence exists between the cell size and the sensitivity to CCl4 among large sized hepatocytes.